ethinyl estradiol/levonorgestrel / Generic mfg. - LARVOL DELTA

MRI-PCOS: Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - P=N/A | N=52 | Completed | Sponsor: University Hospital, Lille | Active, not recruiting ➔ Completed

Trial completion • Polycystic Ovary Syndrome

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (clinicaltrials.gov) - P1 | N=47 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Long-acting Reversible Contraceptives • Metabolic Disorders • Type 2 Diabetes Mellitus

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Atea Pharmaceuticals, Inc.

New P1 trial

Venous thromboembolism in obese hormonal contraceptive users: a large national database study. (PubMed, Res Pract Thromb Haemost) - "Obese users of levonorgestrel + ethinyl estradiol (EE) had a VTE rate of 0.55% vs 0.33% in nonobese users (P = .01, relative risk [RR] = 1.63)...No significant differences were found for progesterone-only HT users. In this large study comparing rates of VTE among obese and nonobese females on HT, a significantly higher risk of VTE was observed among obese females using certain HTs, particularly EE with levonorgestrel, norethindrone, and norgestimate. These results highlight the importance of considering obesity as a key risk factor when prescribing HT, particularly for females with higher body mass index."

Journal • Cardiovascular • Genetic Disorders • Obesity • Venous Thromboembolism

Population Pharmacokinetics of Atogepant for the Prevention of Migraine. (PubMed, Clin Pharmacokinet) - P3 | "The pharmacokinetics of atogepant are similar in healthy participants and patients with CM or EM. Dose adjustments owing to intrinsic factors of age, sex, race, and body weight, or owing to concomitant medications consisting of P-glycoprotein (P-gp) inhibitors, BCRP inhibitors, oral contraceptive components (ethinyl estradiol and levonorgestrel), famotidine, esomeprazole, sumatriptan, acetaminophen, and naproxen are not necessary. Atogepant's popPK model provides a valuable tool for evaluating specific questions for patients, healthcare providers, and regulatory agencies. Integration into other modeling approaches has also aided in model-informed drug development decisions."

Journal • PK/PD data • Breast Cancer • CNS Disorders • Hepatology • Migraine • Oncology • Pain • Renal Disease • Solid Tumor

A Study to Investigate the Effect of AZD6234 and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Jan 2026 ➔ Jul 2026 | Trial primary completion date: Jan 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

RISK OF VENOUS THROMBOEMBOLISM WITH HORMONAL CONTRACEPTION: A NATIONWIDE COHORT STUDY (FIGO 2025) - "We found that the risk of thrombosis with natural estrogen COC was comparable to that of progestin-only pills. The aIRR for natural estrogen COC was lower than that associated with ethinylestradiol and levonorgestrel COC. These results provide evidence for expanding the range of safe hormonal contraceptive options for women with relative risk for venous thromboembolism."

Cardiovascular • Genetic Disorders • Hematological Disorders • Obesity • Venous Thromboembolism

Recent investigations on the impact of levonorgestrel and 17β-ethinylestradiol on melanoma. (PubMed, J Med Life) - "The data obtained showed that levonorgestrel-ethinylestradiol (LG-EE) did not have a toxic effect on healthy cells (HaCaT and JB6 Cl 41-5a) but exhibited a slight proliferative effect on murine skin tumor cells at increasing concentrations...On the B164A5 tumor line, the hormonal combination at a concentration of 5 µM slightly decreased viability and degraded the cell membrane, observing a decrease in confluence and number of cells, as well as the presence of apoptotic bodies, while at the highest dose tested of 15 µM, an opposite effect was recorded with a slight stimulation of murine tumor cells. The results suggest that LG-EE may influence the development of melanoma; however, the evidence is insufficient, and further studies are necessary."

Journal • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor

Bleeding from the nail -a rare and curious case of vicarious menstruation (EADV 2025) - "Differential diagnoses—bleeding diathesis, autoimmune progesterone dermatitis, primary dermatitis—were excluded. Treatment comprised intramuscular leuprolide (3.75 mg monthly), a GnRH analogue for six months, then transition to combined oral contraceptives (ethinylestradiol + levonorgestrel)... Cutaneous vicarious menstruation can present in novel sites such as nail beds and should be considered when bleeding recurs with strict menstrual periodicity in the absence of coagulopathy or autoimmune disease. Histopathology may only show nonspecific vascular congestion and inflammation; absence of ectopic endometrial tissue does not exclude the diagnosis. Hormonal suppression with GnRH analogues followed by combined oral contraceptives is effective and well tolerated."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Hematological Disorders • Immunology • Inflammation • Mood Disorders • Pruritus • Psychiatry

Hormonal Contraceptives and Depression: A Proteomic Analysis Using Neuronal Models. (PubMed, Proteomics Clin Appl) - "This study addresses a pressing clinical need to better understand the potential mental health impacts of widely used hormonal contraceptives. While highly effective for pregnancy prevention, compounds such as ethinyl estradiol and levonorgestrel have repeatedly been associated with increased risk of depressive symptoms, highlighting the importance of investigating their molecular effects on neural systems. To explore this, we applied label-based quantitative proteomics in an undifferentiated human neural progenitor cell model treated with ethinyl estradiol, levonorgestrel, their combination, and the selective androgen receptor modulator S-23. The treatments induced distinct and overlapping changes in protein expression, with enrichment in pathways related to inflammation, oxidative stress, cell adhesion, chromatin dynamics, and programmed cell death-biological processes known to intersect with mechanisms implicated in depression. These findings offer insight into how..."

Journal • CNS Disorders • Depression • Inflammation • Major Depressive Disorder • Mood Disorders • Psychiatry

The Effect of Multiple Oral Doses of a Glycine Transporter 1 Inhibitor, Iclepertin (BI 425809), on the Steady-state Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel: a Phase I Clinical Trial in Healthy Females. (PubMed, Clin Drug Investig) - P1 | "Iclepertin 10 mg had no meaningful effect on the pharmacokinetics of ethinylestradiol and levonorgestrel, suggesting that these drugs can be administered concomitantly."

Journal • P1 data • PK/PD data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

A Study to Investigate the Effect of AZD6234 and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | N=25 ➔ 50

Enrollment change • Genetic Disorders • Obesity

Evaluation of Potential Drug-Drug Interactions with Crinecerfont (ENDO 2025) - "Study 3 (N=25) evaluated the PK of an oral contraceptive (ethinylestradiol/levonorgestrel 30/150 µg) with (Test) or without (Reference) crinecerfont 100 mg. Given the safety profile of crinecerfont, the increase in crinecerfont exposure with ketoconazole was not considered clinically relevant, and no dose adjustments are necessary when administering crinecerfont with CYP3A4 inhibitors. Decreased crinecerfont exposure with rifampin might reduce the efficacy of crinecerfont. Thus, if taken with a strong CYP3A4 inducer, the morning and evening doses of crinecerfont should be increased 2-fold."

Congenital Adrenal Hyperplasia • Endocrine Disorders

Use of medroxyprogesterone acetate and risk of meningiomas: a comparative safety study. (PubMed, Expert Opin Drug Saf) - "MPAuse is linked to a substantially increased risk of meningiomas, underscoringthe importance of assessing its long-term use. Further research is warranted toconfirm these findings and guide clinical practice."

Journal • Brain Cancer • Genetic Disorders • Meningioma • Obesity • Oncology • Solid Tumor

A Study to Assess the Impact of Multiple Doses of AZD6234 on a Single Dose of Combined Oral Contraceptive in Female Participants (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study to Assess the Impact of Multiple Doses of AZD6234 on a Single Dose of Combined Oral Contraceptive in Female Participants (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial • Genetic Disorders • Obesity

A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant (clinicaltrials.gov) - P1 | N=43 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Long-acting Reversible Contraceptives • Obesity

D7960C00011: An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions (clinicaltrials.gov) - P1 | N=59 | Completed | Sponsor: AstraZeneca | Recruiting ➔ Completed

Trial completion • Dyslipidemia

The Potential Role of Ecotoxicological Data in National Essential Medicine Lists: A Cross-Sectional Analysis. (PubMed, Int J Environ Res Public Health) - "This study underscores the limited availability of ecotoxicological data, which hinders environmental risk assessment for medicines. EMLs could serve as a tool to enhance the awareness and data mobilization of pharmaceutical pollution. Incorporating environmental criteria into EMLs could support more sustainable medicine selection and regulatory practices."

Journal

A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

An Atypical Presentation of Pituitary Neurosarcoidosis as Massive Weight Loss and Failure to Thrive in a Young Female. (PubMed, J Assoc Physicians India) - "She was treated with oral preparations of corticosteroids (prednisolone), ethinylestradiol, levonorgestrel, and thyroxine...Neurosarcoidosis with selective hypophyseal involvement, although a rare affliction, should be considered while investigating possible endocrinopathies among middle-aged females. Additionally, clinical evidence in the absence of tissue evidence also requires precedence, especially in cases where histopathology and imaging may not suffice to prove the existence of a disease."

Journal • Anorexia • CNS Disorders • Endocrine Disorders • Eosinophilia • Fatigue • Hematological Disorders • Immunology • Pain • Sarcoidosis • Ventriculomegaly • CRP

The effect of combined oral contraceptives on thrombin generation assessed on ST Genesia- a paired clinical study. (PubMed, Thromb J) - "Although the coagulation factors only changed modestly, the global test thrombin generation performed on ST Genesia showed a considerable change after start of COC."

Journal • Cardiovascular • Venous Thromboembolism • PROS1

Oral contraceptive pill-induced esophagitis: a rare cause of pill esophagitis in a Rwandan woman. (PubMed, Oxf Med Case Reports) - "She presented with epigastric and retrosternal pain and reported daily use of a combined OCP containing ethinyl estradiol and levonorgestrel...Histopathologic evaluation excluded infectious causes, and she improved with proton pump inhibitor therapy and modification of pill consumption habits. This is the first reported case of OCP-induced esophagitis on the African continent and the fifth case overall, and it highlights the importance of awareness of this rare gastrointestinal adverse effect of a commonly used class of drugs, particularly in an area of the world that is promoting the increased uptake of female contraception as a tool for family planning."

Journal • Gastrointestinal Disorder • Pain

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Jun 2025 ➔ Oct 2025 | Trial primary completion date: Feb 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Diabetes • Long-acting Reversible Contraceptives • Metabolic Disorders • Type 2 Diabetes Mellitus

A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives (clinicaltrials.gov) - P1 | N=19 | Completed | Sponsor: Idorsia Pharmaceuticals Ltd. | Not yet recruiting ➔ Completed

Trial completion